- Home
- News
- Topics
- FDA Week
- Inside CMS
- Inside Drug Pricing
- Health Exchange Alert
- Inside TeleHealth
- About Us
Dexamethasone, an inexpensive generic drug, can’t be substituted for Gilead’s higher-priced remdesivir when treating hospitalized coronavirus patients, doctors and analysts say, because the two drugs treat patients at different stages of COVID-19.
Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.
Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.
© 2002-2025. Inside Washington Publishers | Contact Us